Spectrum Vascular Appoints New Executive Leadership Team
Spectrum Vascular Appoints New Executive Leadership Team Spectrum Vascular, a fast-growing provider of vascular access and medication management products designed to reduce healthcare-associated infections (HAIs), has announced the appointment of…
ATED Therapeutics Develops Quick and Easy Blood Test for Detecting Parkinson’s Disease
ATED Therapeutics Develops Quick and Easy Blood Test for Detecting Parkinson’s Disease In a significant stride toward revolutionizing the diagnosis and monitoring of Parkinson’s disease (PD), UK-based biotech company ATED…
Soleo Health Named Exclusive Specialty Pharmacy for Qfitlia™ in Hemophilia Treatment
Soleo Health Named Exclusive Specialty Pharmacy for Qfitlia™ in Hemophilia Treatment Bringing a first-in-class antithrombin-lowering therapy to patients with hemophilia A or B, Soleo Health reinforces its leadership in specialty…
IPUMP Enhances Compliance in SLIT Treatment
IPUMP Enhances Compliance in SLIT Treatment Stallergenes Greer, a global leader in allergy diagnostics and immunotherapy, has announced that it will present compelling findings from its SPEED survey at the…
Aulos Bioscience Begins Phase 2 Dosing of AU-007 and Nivolumab Combo for Melanoma
Aulos Bioscience Begins Phase 2 Dosing of AU-007 and Nivolumab Combo for Melanoma Immuno-oncology innovator Aulos Bioscience has initiated dosing in a new cohort of its ongoing Phase 1/2 clinical…
Mirum Receives FDA Approval for Tablet Version of LIVMARLI
Mirum Receives FDA Approval for Tablet Version of LIVMARLI In a significant advancement for the rare liver disease community, Mirum Pharmaceuticals, Inc. announced today that the U.S. Food and Drug…
New Study Exposes Harmful Effects of IRA’s ‘Pill Penalty’ on Small Molecule Drugs
New Study Exposes Harmful Effects of IRA’s ‘Pill Penalty’ on Small Molecule Drugs A recently published peer-reviewed study is shedding light on the unintended yet far-reaching consequences of the Inflation…
Exicure Approaches Phase 2 Completion for GPC-100 in Multiple Myeloma Treatment
Exicure Approaches Phase 2 Completion for GPC-100 in Multiple Myeloma Treatment Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company advancing novel small molecule therapeutics for immuno-oncology and hematological malignancies, announced…
AdvanCell Announces $18M MRFF Funding for Targeted Prostate Cancer Therapy
AdvanCell Announces $18M MRFF Funding for Targeted Prostate Cancer Therapy AdvanCell, a clinical-stage radiopharmaceutical company at the forefront of targeted cancer therapeutics, has received a significant boost from the Australian…
FDA Approves VYVGART Hytrulo Prefilled Syringe with ENHANZE for Self-Injection in gMG and CIDP
FDA Approves VYVGART Hytrulo Prefilled Syringe with ENHANZE for Self-Injection in gMG and CIDP In a major development for patients suffering from chronic neuromuscular autoimmune disorders, Halozyme Therapeutics, Inc. announced…
Vertex’s Paul Negulescu, Ph.D., Wins 2025 Gairdner Award for Cystic Fibrosis Breakthroughs
Vertex’s Paul Negulescu, Ph.D., Wins 2025 Gairdner Award for Cystic Fibrosis Breakthroughs In a landmark moment for both Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and the broader scientific community, Paul Negulescu,…
Bruker Enhances IR Biotyper® for Hospital Hygiene with NGS Reflex Testing
Bruker Enhances IR Biotyper® for Hospital Hygiene with NGS Reflex Testing At the ESCMID Global 2025 conference, Bruker’s Microbiology and Infection Diagnostics division made a major announcement regarding the expansion…